I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Attn: Box Missing Parts
Washington, D.C. 20231

On December 13, 2000
TOWNSEND and TOWNSEND and CREW LLP
Paula Tault Hurley

PATENT
Attorney Docket No.: 15270J-004740US



4-11-01 ST

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 02 2001
TECH CENTER 1600/2900

In re application of:

SCHENK, Dale B.

Application No.: 09/322,289

Filed: May 28, 1999

For: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE

Examiner: Turner, Sharon L.

Art Unit: 1647

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed September 29, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 11, line 25, insert --(SEQ ID NO:1)-- after "-Ala-OH".

On page 50, line 11, replace "NH2-DAEFRHDSGYEVC-COOH" with --NH_2-DAEFRHDSGYEVC-COOH (SEQ ID NO:2)--.

On page 50, line 12, replace "NH2-DAEFRC-COOH" with --NH_2-DAEFRC-COOH (SEQ ID NO:3)--.